PRESS RELEASE: 'Corporate Reputation of Pharma in 2017 - the Global Patient Perspective' 'Corporate Reputation of Pharma in 2017 - the Patient Perspective'
EMBARGOED PRESS RELEASE: 6AM GMT, THURSDAY, APRIL 5TH 2018: ~ Contact: Alex Wyke ~ Tel: +44-(0)1547-520-965 ~ Email: report@patient-view.com
ABOUT THIS 2017 REPORT AND SURVEY
![]() London, April 5th, 2018. The 'Corporate Reputation of Pharma in 2017' report is based on the findings of a PatientView November 2017-February 2018 survey exploring the views of 1,330 patient groups worldwide. The report provides feedback (from the perspective of these patient groups) on the corporate reputation of the pharma industry during 2017, as well as on the performance of 46 pharma companies at 12 key indicators that influence corporate reputation. The Corporate-Reputation survey is now in its 7th edition—thus, 7 years of historical data are available. In addition, we incorporated several important new indicators of corporate reputation into the 2017 survey—to reflect the changing, and more demanding, relationships that now exist between patient groups and pharma companies. The 12 indicators of corporate reputation used to assess 46 pharma companies in 2017 ![]() The 46 companies assessed in this 2017 report AbbVie I Acorda Therapeutics I Allergan I Almirall I Amgen I Astellas Pharma I AstraZeneca I Bayer I Bial I Biogen I Boehringer Ingelheim I Bristol-Myers Squibb I Celgene I Chiesi Farmaceutici I CSL Behring I Daiichi Sankyo I Eisai I Eli Lilly (Lilly) I Ferring I Gedeon Richter I Gilead Sciences I Grifols I Grünenthal I GSK I Ipsen I Janssen (Pharmaceutical Companies of Johnson & Johnson) I LEO Pharma I Lundbeck I Menarini I Merck & Co I Merck KGaA I Novartis I Novo Nordisk I Octapharma I Otsuka I Pierre Fabre Laboratories I Pfizer I Roche I Sanofi I Servier I Shire I Takeda I Teva I UCB I Vertex Pharmaceuticals I ViiV Healthcare. ![]() HOW DID INDUSTRY FARE? In 2017, patient-group attitudes towards pharma improved, after plummeting in 2016.
PHARMA ALSO IMPROVED IN KEY ACTIVITIES IN 2017 ...
BUT ...
![]() Why these results? On the negative side ... Major structural issues appear to be damaging the pharma industry’s R&D productivity. For example, companies are increasingly finding difficulty in differentiating their products from those of their competitors—and they are also having trouble tackling unmet patient needs, and innovating. Although 2017—unlike previous years—brought few, if any, large-scale safety problems, safety remains a perennial concern for most patient groups. Mental-health patient groups—which represent the largest proportion of respondents to the Corporate-Reputation survey (8% in 2017)—particularly emphasise the subject of patient safety. Patient groups, too, hold rising expectations that pharma will improve on its transparency levels; awareness of transparency indices is corresponding up among them. In addition (in the US, at least), patent/licencing battles between pharmaceutical companies have gained media attention—especially in light of President Trump’s continuing ‘politicisation’ of the topics of pharma pricing and profits. Why these results? On the positive side ... The fact that the pharma industry as a whole saw an overall increase in its corporate reputation among patient groups during 2017 is probably due to the efforts made by the global headquarters of companies to improve corporate integrity. Integrity is a facet of company-wide authenticity, and forms one of the nine ‘attributes’ defined by PatientView as essential to successful corporate patient centricity [see details about the PatientView publication, Being Patient Centric]. A boost in the industry’s integrity may have been made possible by a reduction in mergers and acquisitions during 2017—a trend that gives companies a breathing space to reorganise, and to focus more on patients, and less on worrying about being taken over by competitors (or whether to take over competitors). Although the evidence suggests that a centralised approach is improving the authenticity of companies, what still remains to be seen is whether enough is being done to lift patient-group perceptions of companies across PatientView’s other eight ‘attributes’ of patient centricity (including patient safety, transparency, and R&D). ![]()
HOW COMPANIES PERFORMED Companies with the "Best" corporate reputation in 2017, as assessed by patient groups familiar with the company Ranking is measured by patient groups familiar with a company. Such patient groups provide feedback on the public-domain persona of the companies.
Overall top-tier companies. Each company could be placed into one of three tiers of corporate reputation (top, middle, or lower), depending on its average performance across the 12 indicators of corporate reputation. Ten companies reached a score that allowed them to rank in the overall top tier for all indicators of corporate reputation in 2017. In order of 1 to 10: ViiV, AbbVie, Gilead Sciences, Novartis, Janssen, Roche, Lundbeck, UCB, Novo Nordisk, and Pfizer. Pfizer’s jump of two places in the overall rankings among patient groups familiar with it (up to 10th in 2017 from 12th in 2016), moved the company into the top tier. Higher-flying companies among patient groups familiar with the company (represents a company's public image) 2017's biggest rises up the rankings among patient groups familiar with a company were achieved by Merck KGaA and Boehringer Ingelheim. Though not to detract from the success of these latter companies’ achievements, their increases were partly due to changes in 2017 in PatientView's survey methodology and analyses. Rankings of individual pharma companies among patient groups familar with the company, 2017 v. 2016, ordered HIGH to LOW ![]() Companies with the "Best" corporate reputation, as assessed by patient groups that work or partner with the company The companies that saw the biggest rises in overall positioning for corporate reputation, 2017 v. 2016—according to their patient-group partners (represents a private, internal image of a company) ![]() A slightly different picture is attained if the corporate reputation of companies is assessed by their patient-group partners. Aside from Boehringer Ingelheim and Merck KGaA, the most striking improvements in company performance at corporate reputation in 2017 were reported by the patient-group partners of LEO Pharma, Ipsen, Menarini, Lundbeck, and Biogen.
* NOTE OF QUALIFICATION ABOUT THE NEW INDICATORS OF CORPORATE REPUTATION USED IN THE 2017 SURVEY: A number of respondent patient groups—even if they worked with pharma—either did not know the answers to the questions about the new indicators, or felt that none of the companies qualified for election as “Best” at the new indicators. Hence, the very low scores sometimes reported for the new indicators, particularly in the middle and lower tiers of the league tables. Percentage of patient groups stating that “None" of the 46 companies were “Best” for each indicator (indicator by indicator) ![]() NET PROMOTER SCORE (NPS) For the first time, PatientView’s 2017 Corporate-Reputation survey utilised a Net Promoter Score (NPS) question. The question asked patient groups working/partnering with a company whether they would recommend that company to another patient group. NPS is a standard management tool. It asks whether a customer would recommend a company to another person. As such, the NPS is typically used to measure a customer’s loyalty to the company. In accordance with standard NPS measures, customers are asked to score its likelihood of recommendation on a scale of 0 to 10 (with ‘10’ being a definite recommendation of the company, and ‘0’ being definitely no recommendation of the company). The NPS score is obtained by calculating the percentage of customers that score a company either '9' or '10' (promoters), and subtracting the percentage of customers that score a company anywhere from '0' to '6' (dectractors). Scores of 7 or 8 are considered passives, and not counted at all. Scores above +40% are considered excellent. Scores below zero suggest customer discontent with the company. Top scores for NPS among 2017's 46 featured pharma companies are shown below:
[The greatest divergence between NPS and PatientView’s league tables (as assessed by patient groups that work with the company) is found among the companies that sit near the bottom of the tables. These latter companies posted inconsistent scores (higher and lower) for the 12 indicators of corporate reputation. Such variations may explain why the NPS scores and the location of the latter companies in the league table can be so different.] For further information on this report, please use contact details at the top of this press release ![]() ![]() ~END OF PRESS RELEASE~
|